{"id":"NCT02462928","sponsor":"Allergan","briefTitle":"A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration","officialTitle":"Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-25","primaryCompletion":"2018-04-18","completion":"2019-06-19","firstPosted":"2015-06-04","resultsPosted":"2020-07-28","lastUpdate":"2020-07-28"},"enrollment":939,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Abicipar Pegol","otherNames":["AGN-150998"]},{"type":"DRUG","name":"Ranibizumab","otherNames":["LucentisÂ®"]},{"type":"OTHER","name":"Sham Procedure","otherNames":[]}],"arms":[{"label":"Abicipar Pegol 2 mg (2Q8)","type":"EXPERIMENTAL"},{"label":"Abicipar Pegol 2 mg (2Q12)","type":"EXPERIMENTAL"},{"label":"Ranibizumab 0.5 mg (rQ4)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.","primaryOutcome":{"measure":"Percentage of Participants With Stable Vision at Week 52","timeFrame":"Baseline to Week 52","effectByArm":[{"arm":"Abicipar Pegol 2 mg (2Q8)","deltaMin":91.7,"sd":null},{"arm":"Abicipar Pegol 2 mg (2Q12)","deltaMin":91.2,"sd":null},{"arm":"Ranibizumab 0.5 mg (rQ4)","deltaMin":95.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":151,"countries":["United States","Argentina","Austria","Chile","Colombia","Czechia","France","Germany","Hong Kong","Israel","Latvia","New Zealand","Philippines","Singapore","South Korea","Spain","Switzerland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":312},"commonTop":["Nasopharyngitis","Conjunctival haemorrhage","Neovascular age-related macular degeneration","Visual acuity reduced","Eye pain"]}}